Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Prospective Trial to Evaluate the Tolerability, Safety and Maintained Efficacy of a Transition to Paliperidone ER in Subjects With Schizophrenia Previously Unsuccessfully Treated With Other Oral Antipsychotics

NCT00757705 is registered in ClinicalTrials.gov with Johnson & Johnson Taiwan Ltd as lead sponsor.

NCT NCT00757705
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00757705 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Prospective Trial to Evaluate the Tolerability, Safety and Maintained Efficacy of a Transition to Paliperidone ER in Subjects With Schizophrenia Previously Unsuccessfully Treated With Other Oral Antipsychotics
Lead sponsor
Johnson & Johnson Taiwan Ltd
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2008
Completion date
May 31, 2009
Enrollment
299 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia